Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

156 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
GSTA1 Genetic Variants and Conditioning Regimen: Missing Key Factors in Dosing Guidelines of Busulfan in Pediatric Hematopoietic Stem Cell Transplantation.
Nava T, Rezgui MA, Uppugunduri CRS, Curtis PH, Théoret Y, Duval M, Daudt LE, Ansari M, Krajinovic M, Bittencourt H. Nava T, et al. Among authors: bittencourt h. Biol Blood Marrow Transplant. 2017 Nov;23(11):1918-1924. doi: 10.1016/j.bbmt.2017.07.022. Epub 2017 Aug 12. Biol Blood Marrow Transplant. 2017. PMID: 28807770 Free article.
Patient socioeconomic status as a prognostic factor for allo-SCT.
Silla L, Fischer GB, Paz A, Daudt LE, Mitto I, Katz B, da Graça Grossini M, Bittencourt HN, Jochims A, Fogliatto L, Bittar CM, Friedrisch JR, Bittencourt RI. Silla L, et al. Among authors: bittencourt hn, bittencourt ri. Bone Marrow Transplant. 2009 Apr;43(7):571-7. doi: 10.1038/bmt.2008.358. Epub 2008 Nov 3. Bone Marrow Transplant. 2009. PMID: 18978820
Excess of veno-occlusive disease in a randomized clinical trial on a higher trigger for red blood cell transfusion after bone marrow transplantation: a canadian blood and marrow transplant group trial.
Robitaille N, Lacroix J, Alexandrov L, Clayton L, Cortier M, Schultz KR, Bittencourt H, Duval M. Robitaille N, et al. Among authors: bittencourt h. Biol Blood Marrow Transplant. 2013 Mar;19(3):468-73. doi: 10.1016/j.bbmt.2012.12.002. Epub 2012 Dec 7. Biol Blood Marrow Transplant. 2013. PMID: 23220014 Free article. Clinical Trial.
Glutathione S-transferase gene variations influence BU pharmacokinetics and outcome of hematopoietic SCT in pediatric patients.
Ansari M, Rezgui MA, Théoret Y, Uppugunduri CR, Mezziani S, Vachon MF, Desjean C, Rousseau J, Labuda M, Przybyla C, Duval M, Champagne M, Peters C, Bittencourt H, Krajinovic M; Pediatric Disease Working Parties of the European Blood and Marrow Transplant Group. Ansari M, et al. Among authors: bittencourt h. Bone Marrow Transplant. 2013 Jul;48(7):939-46. doi: 10.1038/bmt.2012.265. Epub 2013 Jan 7. Bone Marrow Transplant. 2013. PMID: 23292236 Clinical Trial.
The clinical relevance of pre-formed anti-HLA and anti-MICA antibodies after cord blood transplantation in children.
Ansari M, Uppugunduri CR, Ferrari-Lacraz S, Bittencourt H, Gumy-Pause F, Chalandon Y, Tiercy JM, Schechter T, Gassas A, Doyle JD, Dupuis L, Duval M, Krajinovic M, Villard J. Ansari M, et al. Among authors: bittencourt h. PLoS One. 2013 Aug 19;8(8):e72141. doi: 10.1371/journal.pone.0072141. eCollection 2013. PLoS One. 2013. PMID: 23977232 Free PMC article.
Association between busulfan exposure and outcome in children receiving intravenous busulfan before hematopoietic stem cell transplantation.
Ansari M, Théoret Y, Rezgui MA, Peters C, Mezziani S, Desjean C, Vachon MF, Champagne MA, Duval M, Krajinovic M, Bittencourt H; Pediatric Disease Working Parties of the European Blood and Marrow Transplant Group. Ansari M, et al. Among authors: bittencourt h. Ther Drug Monit. 2014 Feb;36(1):93-9. doi: 10.1097/FTD.0b013e3182a04fc7. Ther Drug Monit. 2014. PMID: 24061446
The association of cytochrome P450 genetic polymorphisms with sulfolane formation and the efficacy of a busulfan-based conditioning regimen in pediatric patients undergoing hematopoietic stem cell transplantation.
Uppugunduri CR, Rezgui MA, Diaz PH, Tyagi AK, Rousseau J, Daali Y, Duval M, Bittencourt H, Krajinovic M, Ansari M. Uppugunduri CR, et al. Among authors: bittencourt h. Pharmacogenomics J. 2014 Jun;14(3):263-71. doi: 10.1038/tpj.2013.38. Epub 2013 Oct 29. Pharmacogenomics J. 2014. PMID: 24165757
Allogeneic human mesenchymal stem cell therapy (remestemcel-L, Prochymal) as a rescue agent for severe refractory acute graft-versus-host disease in pediatric patients.
Kurtzberg J, Prockop S, Teira P, Bittencourt H, Lewis V, Chan KW, Horn B, Yu L, Talano JA, Nemecek E, Mills CR, Chaudhury S. Kurtzberg J, et al. Among authors: bittencourt h. Biol Blood Marrow Transplant. 2014 Feb;20(2):229-35. doi: 10.1016/j.bbmt.2013.11.001. Epub 2013 Nov 8. Biol Blood Marrow Transplant. 2014. PMID: 24216185 Free article.
Calcineurin inhibitor-free graft-versus-host disease prophylaxis with sirolimus and mycophenolate mofetil in a second allogeneic stem cell transplantation for engraftment failure and rituximab-refractory Epstein-Barr virus-induced posttransplant lymphoproliferative disease.
Ceppi F, Duval M, Teira P, Therrien R, Ovetchkine P, Mallette B, Bittencourt H. Ceppi F, et al. Among authors: bittencourt h. J Pediatr Hematol Oncol. 2014 Jul;36(5):e319-21. doi: 10.1097/MPH.0000000000000066. J Pediatr Hematol Oncol. 2014. PMID: 24977404
156 results